Adagio Medical Holdings, INC. (ADGM) — SEC Filings

Overview

Adagio Medical Holdings, INC. (ADGM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 8, 2026: Adagio Medical Holdings, Inc. filed an 8-K on April 8, 2026, reporting other events and financial statements. The filing includes an XBRL version of the 8-K and exhibits, along with XBRL taxonomy extensions.

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 4 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Adagio Medical Holdings, INC. is neutral.

Filing Type Overview

Adagio Medical Holdings, INC. (ADGM) has filed 24 8-K, 2 EFFECT, 2 424B3, 2 10-K, 5 10-Q, 1 DEF 14A, 1 10-K/A, 1 S-1/A, 2 S-1, 2 SC 13G, 2 8-K/A with the SEC between Aug 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (44)

• Adagio Medical Holdings Files 8-K — 8-K · Apr 8, 2026 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on April 8, 2026, reporting other events and financial statements. The filing includes an XBRL version of the 8-K and
• Adagio Medical Holdings SEC Filing Effectiveness — EFFECT · Apr 6, 2026 Risk: low
  Adagio Medical Holdings, Inc. filed an EFFECT form on April 6, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No
• Adagio Medical Holdings SEC Filing Effectiveness — EFFECT · Apr 6, 2026 Risk: low
  Adagio Medical Holdings, Inc. filed an EFFECT form with the SEC on April 6, 2026, indicating the effectiveness of a registration statement. The effectiveness da
• 424B3 Filing — 424B3 · Mar 27, 2026
• 424B3 Filing — 424B3 · Mar 27, 2026
• Adagio Medical's VT Ablation System Shows Promise Amidst Safety Concerns — 10-K · Mar 27, 2026 Risk: high
  Adagio Medical Holdings, Inc. (ADGM) reported a market value of common stock held by non-affiliates at $7.0 million as of June 30, 2025, with 22,210,459 shares
• 8-K Filing — 8-K · Mar 27, 2026
• 8-K Filing — 8-K · Dec 16, 2025
• Adagio Medical Holdings Reports Director/Officer Changes — 8-K · Dec 11, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on December 11, 2025, reporting changes related to its directors and officers, including elections and appointments.
• Adagio Medical's Cash Dries Up Amid Soaring Losses, R&D Spend — 10-Q · Nov 12, 2025 Risk: high
  Adagio Medical Holdings, Inc. (ADGM) reported a significant net loss of $21.778 million for the nine months ended September 30, 2025, a substantial increase fro
• Adagio Medical Sets Dec. 15 Virtual Shareholder Meeting for Director Election, Auditor Ratification — DEF 14A · Nov 4, 2025 Risk: low
  Adagio Medical Holdings, Inc. (ADGM) is holding its Annual Meeting of Stockholders on December 15, 2025, virtually at 10:00 a.m. Pacific Time. The primary purpo
• Adagio Medical Holdings Files 8-K on Shareholder Nominations — 8-K · Oct 24, 2025 Risk: medium
  Adagio Medical Holdings, Inc. filed an 8-K on October 23, 2025, regarding shareholder nominations under Exchange Act Rule 14a-11. The filing details the company
• Adagio Medical Holdings Files 8-K — 8-K · Oct 20, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on October 20, 2025, reporting on other events and financial statements. The company, formerly known as Aja Holdco, I
• Adagio Medical Holdings Enters Material Agreement — 8-K · Oct 15, 2025 Risk: medium
  On October 14, 2025, Adagio Medical Holdings, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. Th
• Adagio Medical Holdings Files 8-K — 8-K · Oct 10, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on October 10, 2025, reporting other events and financial statements. The company, formerly known as Aja Holdco, Inc.
• Adagio Medical Holdings Files 8-K — 8-K · Oct 1, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on October 1, 2025, reporting other events and financial statements. The company, formerly known as Aja Holdco, Inc.
• Adagio Medical Holdings Director Departs, New Director Elected — 8-K · Sep 8, 2025 Risk: medium
  Adagio Medical Holdings, Inc. announced on September 3, 2025, the departure of director David L. Johnson and the election of new director Michael J. O'Malley. T
• Adagio Medical Holdings Files 10-Q for Q2 2025 — 10-Q · Aug 14, 2025 Risk: medium
  Adagio Medical Holdings, Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly Aja Holdco, Inc. until January 4, 2024, is based in Lagu
• Adagio Medical Holdings Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulati
• Adagio Medical Holdings Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
• Adagio Medical Holdings Files 10-Q for Q1 2025 — 10-Q · May 15, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Aja Holdco, Inc., changed its name on January 4, 2024.
• Adagio Medical Holdings Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Aja H
• Adagio Medical Holdings: Director Departs, New Director Appointed — 8-K · Apr 23, 2025 Risk: low
  Adagio Medical Holdings, Inc. announced on April 17, 2025, the departure of director Dr. David L. D. Smith and the appointment of Dr. Michael J. McGinley as a n
• Adagio Medical Holdings Files 8-K — 8-K · Apr 2, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on April 2, 2025, reporting on its financial condition and results of operations as of March 31, 2025. The filing als
• Adagio Medical Holdings Files 2024 Annual Report — 10-K · Mar 27, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly Aja Holdco, Inc. until January 4, 2024, is base
• Adagio Medical Holdings, Inc. Announces Director Changes and Officer Appointments — 8-K · Mar 17, 2025 Risk: medium
  Adagio Medical Holdings, Inc. announced on March 11, 2025, the departure of director David L. Doman and the election of new director Michael J. O'Malley. The co
• Adagio Medical Holdings Announces Board and Executive Changes — 8-K · Mar 4, 2025 Risk: medium
  Adagio Medical Holdings, Inc. announced on February 28, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the compa
• Adagio Medical Holdings Files 8-K — 8-K · Feb 28, 2025 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on February 28, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, for
• Adagio Medical Terminates Material Agreement — 8-K · Feb 5, 2025 Risk: medium
  Adagio Medical Holdings, Inc. filed an 8-K on February 5, 2025, to report the termination of a material definitive agreement. The agreement was terminated as of
• Adagio Medical Holdings Files S-1/A Amendment — S-1/A · Feb 4, 2025 Risk: medium
  Adagio Medical Holdings, Inc. filed a Pre-Effective Amendment No. 1 to its Form S-1 Registration Statement on February 4, 2025. This filing relates to the Secur
• Adagio Medical Holdings Files for IPO — S-1 · Jan 14, 2025 Risk: medium
  Adagio Medical Holdings, Inc. filed an S-1 form on January 14, 2025, to register its securities for a potential initial public offering. The company, formerly k
• Adagio Medical Holdings Files 8-K: Agreement, Delisting Notice — 8-K · Jan 6, 2025 Risk: high
  Adagio Medical Holdings, Inc. announced on January 2, 2025, that it entered into a material definitive agreement. The company also provided notice of delisting
• Adagio Medical Faces Nasdaq Delisting, Appoints New Leadership — 8-K · Dec 23, 2024 Risk: high
  Adagio Medical Holdings, Inc. announced on December 19, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rule
• Adagio Medical Holdings Announces Key Executive and Board Changes — 8-K · Dec 16, 2024 Risk: medium
  Adagio Medical Holdings, Inc. announced on December 11, 2024, the entry into a material definitive agreement, the departure of directors or certain officers, th
• Adagio Medical Holdings, Inc. Q3 2024 10-Q Filing — 10-Q · Nov 14, 2024 Risk: medium
  Adagio Medical Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $21.28 million and total liabilities
• SC 13G Filing — SC 13G · Nov 13, 2024
• Adagio Medical Holdings Files 8-K/A Amendment — 8-K/A · Nov 4, 2024 Risk: low
  Adagio Medical Holdings, Inc. filed an amendment (No. 2) to its Form 8-K on November 4, 2024, reporting events as of July 31, 2024. The filing primarily concern
• Adagio Medical Restates Financials — 8-K · Nov 1, 2024 Risk: high
  Adagio Medical Holdings, Inc. announced on November 1, 2024, that it will not rely on previously issued financial statements. This decision impacts financial re
• Adagio Medical Holdings Files for IPO — S-1 · Sep 13, 2024 Risk: medium
  Adagio Medical Holdings, Inc. filed an S-1 form on September 13, 2024, indicating its intention to go public. The company, formerly known as Aja Holdco, Inc. un
• Adagio Medical Holdings Files Q2 10-Q — 10-Q · Aug 26, 2024 Risk: low
  Adagio Medical Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Aja Holdco, Inc., changed its name on January 4, 2024. T
• Adagio Medical Holdings, Inc. Renames — 8-K · Aug 19, 2024 Risk: low
  Adagio Medical Holdings, Inc. filed an 8-K on August 19, 2024, to report a change in its corporate name from Aja Holdco, Inc. to Adagio Medical Holdings, Inc.,
• Adagio Medical Holdings Files 8-K/A Amendment — 8-K/A · Aug 14, 2024 Risk: low
  Adagio Medical Holdings, Inc. filed an amendment (8-K/A) on August 14, 2024, to its previous report concerning the completion of an acquisition or disposition o
• SC 13G Filing — SC 13G · Aug 12, 2024
• Adagio Medical Holdings Reports Key Corporate Events — 8-K · Aug 6, 2024 Risk: medium
  Adagio Medical Holdings, Inc. filed an 8-K on August 6, 2024, reporting several material events. These include the entry into a material definitive agreement, c

Risk Profile

Risk Assessment: Of ADGM's 38 recent filings, 5 were flagged as high-risk, 13 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Todd Usen
• James L. Cox, M.D.
• Deborah Kaster
• David L. Johnson
• Michael J. O'Malley
• Dr. David L. D. Smith
• Dr. Michael J. McGinley
• David L. Doman
• Robert J. Palmisano
• David J. Miller

Industry Context

The global electrophysiology (EP) device market is a significant and rapidly growing sector, valued at approximately $14 billion in 2025 and projected to exceed $33 billion by 2033, with a compound annual growth rate (CAGR) of 13%. This growth is driven by an increasing prevalence of cardiac arrhythmias and advancements in ablation technologies. Adagio Medical's focus on Ventricular Tachycardia (VT) addresses a specific, underserved segment within this broader market, where current treatment options may have limitations.

Top Tags

financial-reporting (6) · financial-statements (5) · financials (4) · registration-statement (4) · sec-filing (4) · filing (3) · corporate-actions (3) · 10-Q (3) · amendment (3) · 8-k (2)

Key Numbers

• Effectiveness Date: 2026-04-03 — The date the registration statement became effective.
• Filing Date: 2026-04-06 — The date the SEC accepted the filing.
• Market value of common stock held by non-affiliates: $7.0M — As of June 30, 2025, indicating a small market capitalization.
• Shares of common stock outstanding: 22,210,459 — As of March 23, 2026, representing the total shares available.
• Completion of FULCRUM-VT Pivotal FDA IDE study enrollment: October 2025 — Key milestone for regulatory approval pathway.
• Breakthrough Device Designation by the FDA: April 2025 — Accelerates review process for vCLAS™ Cryoablation System.
• Acute clinical success rate in FULCRUM-VT trial: 97.4% — High efficacy in eliminating target ventricular arrhythmias.
• Major adverse event rate in FULCRUM-VT trial: 2.4% — Safety concern, including device-related deaths.
• Peri-procedural deaths definitely related to investigational device: 0.5% — Significant safety issue for FDA approval.
• Global market for electrophysiology (EP) devices: $14B — Total market size in 2025, indicating significant opportunity.
• Projected compound annual growth rate (CAGR) for EP market: 13% — Expected growth to over $33 billion by 2033.
• SEC File Number: 001-42199 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 99-1151466 — Tax identification number for the company.
• Net Loss: $21.778M — for the nine months ended September 30, 2025, compared to $3.606M net income in the prior year successor period.
• Revenue: $0 — for the nine months ended September 30, 2025, down from $132K in the prior year successor period.

Related Companies

ADGI

Frequently Asked Questions